Drug Profile


Alternative Names: E 5880

Latest Information Update: 17 Nov 2006

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class Antiallergics; Antiasthmatics; Antiplatelets
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Disseminated intravascular coagulation

Most Recent Events

  • 10 Feb 2000 Discontinued-II for Disseminated intravascular coagulation in Japan (Injection)
  • 25 Jan 1999 E 5880 is now called minopafant (INN)
  • 18 Aug 1997 No-Development-Reported for Asthma in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top